DDC Protein

Aromatic L-Amino Acid Decarboxylase (AADC)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">DDC Protein</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">L-DOPA/Carbidopa</td>
<td>Carbidopa blocks peripheral AADC</td>
</tr>
<tr>
<td class="label">L-DOPA/Benserazide</td>
<td>Peripheral AADC inhibition</td>
</tr>
<tr>
<td class="label">Gene therapy (AAV-AADC)</td>
<td>Enhance striatal AADC</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/parkinson's-disease" style="color:#ef9a9a">Parkinson's disease</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-d3a64f5c" style="color:#ce93d8" title="Score: 0.41">Correcting Gut Microbial Dopamine Imbala...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">10 edges</a></td>
</tr>
</table>

Introduction

Dopamine decarboxylase (DDC), also known as aromatic L-amino acid decarboxylase (AADC), is a pivotal pyridoxal phosphate (vitamin B6)-dependent enzyme that catalyzes the final step in the biosynthesis of monoamine neurotransmitters. Specifically, AADC converts L-3,4-dihydroxyphenylalanine (L-DOPA) to dopamine and 5-hydroxytryptophan (5-HTP) to serotonin, making it essential for catecholamine and indoleamine signaling throughout the central and peripheral nervous systems. [@da1990]

Aromatic L-Amino Acid Decarboxylase (AADC)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">DDC Protein</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">L-DOPA/Carbidopa</td>
<td>Carbidopa blocks peripheral AADC</td>
</tr>
<tr>
<td class="label">L-DOPA/Benserazide</td>
<td>Peripheral AADC inhibition</td>
</tr>
<tr>
<td class="label">Gene therapy (AAV-AADC)</td>
<td>Enhance striatal AADC</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/parkinson's-disease" style="color:#ef9a9a">Parkinson's disease</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-d3a64f5c" style="color:#ce93d8" title="Score: 0.41">Correcting Gut Microbial Dopamine Imbala...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">10 edges</a></td>
</tr>
</table>

Introduction

Dopamine decarboxylase (DDC), also known as aromatic L-amino acid decarboxylase (AADC), is a pivotal pyridoxal phosphate (vitamin B6)-dependent enzyme that catalyzes the final step in the biosynthesis of monoamine neurotransmitters. Specifically, AADC converts L-3,4-dihydroxyphenylalanine (L-DOPA) to dopamine and 5-hydroxytryptophan (5-HTP) to serotonin, making it essential for catecholamine and indoleamine signaling throughout the central and peripheral nervous systems. [@da1990]

This 480 amino acid enzyme is expressed primarily in catecholaminergic and serotonergic neurons of the brain, as well as in peripheral tissues including the liver, kidneys, and gastrointestinal tract. AADC deficiency caused by DDC gene mutations results in a severe neurometabolic disorder characterized by developmental delay, movement disorders, and autonomic dysfunction, highlighting the enzyme's critical role in neural development and function. [@berry2014]

In neurodegenerative diseases, AADC activity becomes a therapeutic target, particularly in Parkinson's disease where the enzyme converts exogenously administered L-DOPA to dopamine. Understanding AADC regulation and its role in neurotransmitter metabolism provides insights into both disease mechanisms and treatment strategies. [@hofling2016]

Structure

DDC Protein is a 480 amino acid protein encoded by the DDC gene (located on chromosome 7p12.2). The protein localizes primarily to the cytosol of neurons and is characterized by:

• Molecular weight: ~54 kDa
• Primary structure: 480 amino acids
• Cofactor requirement: Pyridoxal 5'-phosphate (PLP, vitamin B6)
• Subunit structure: Homodimeric (active form)
• Enzyme classification: EC 4.1.1.28 (L-tryptophan decarboxylase)

Normal Function

Aromatic L-amino acid decarboxylase catalyzes the following reactions:

Dopamine Biosynthesis

This reaction represents the final enzymatic step in dopamine synthesis, following tyrosine hydroxylation by tyrosine hydroxylase (TH) and aromatic amino acid hydroxylase (AAAH).

Serotonin Biosynthesis

Similarly, AADC completes serotonin biosynthesis following tryptophan hydroxylation by tryptophan hydroxylase (TPH).

Regional Distribution

AADC is expressed in:

• Substantia nigra pars compacta: Dopamine neurons projecting to striatum
• Ventral tegmental area: Dopamine neurons projecting to cortex and limbic system
• Raphe nuclei: Serotonin neurons throughout the forebrain
• Locus coeruleus: Noradrenergic neurons
• Peripheral tissues: Adrenal medulla, enteric nervous system

Physiological Roles

Role in Disease

Parkinson's Disease

While primarily a disorder of dopaminergic neuron loss, AADC plays a complex role in PD:

• Residual AADC activity: Surviving neurons maintain some L-DOPA converting capacity
• AADC upregulation: Compensatory increase in AADC expression in early PD
• AADC as therapeutic target: Gene therapy approaches aim to enhance AADC in striatum
• Fluctuating efficacy: Changes in AADC activity may contribute to L-DOPA response variability

AADC Deficiency

Biallelic mutations in the DDC gene cause this severe autosomal recessive neurometabolic disorder:

• Onset: Infancy
• Core symptoms:
• Severe developmental delay
• Hypotonia
• Movement disorders (dystonia, dyskinesias, oculogyric crises)
• Autonomic dysfunction (temperature instability, sweating, hypotension)
• Seizures
• Treatment: Pyridoxine supplementation, dopamine agonists, MAO inhibitors
• Prognosis: Variable; early diagnosis improves outcomes

Alzheimer's Disease

AADC alterations in AD include:

• Reduced AADC activity in cortical and hippocampal regions
• Interaction with cholinergic system dysfunction
• Potential for combined neurotransmitter targeted therapy

Therapeutic Targeting

Parkinson's Disease

AADC is central to PD treatment:

The addition of carbidopa or benserazide (AADC inhibitors) to L-DOPA prevents peripheral conversion, ensuring central dopamine synthesis and reducing side effects.

Experimental Approaches

• Gene therapy: AAV-mediated AADC delivery to striatum (in clinical trials)
• Cell therapy: Transplantation of AADC-expressing cells
• Small molecule AADC activators: Under investigation

Key Publications

See Also

• [DDC Gene](/genes/ddc)
• [Dopamine Biosynthesis](/mechanisms/dopamine-biosynthesis)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Tyrosine Hydroxylase](/proteins/tyrosine-hydroxylase-protein)
• [L-DOPA Therapy](/mechanisms/ldopa-therapy)
• [Substantia Nigra](/cell-types/substantia-nigra-pars-compacta)

External Links

• [UniProt: P20705](https://www.uniprot.org/uniprot/P20705)
• [GeneCards: DDC](https://www.genecards.org/cgi-bin/carddisp.pl?gene=DDC)
• [OMIM: AADC Deficiency](https://omim.org/entry/608643)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Correcting Gut Microbial Dopamine Imbalance to Support Systemic Dopaminergic Function](/hypothesis/h-d3a64f5c) — <span style="color:#ffd54f;font-weight:600">0.42</span> · Target: DDC